Perspectum Lands Top Spot in Alantra Pharma Fast 50 Rankings. Read more

Our latest news for ‘NAFLD’

We are proud to be leading the way in providing more patient-centric solutions for people with liver disease that helps them and their physician make informed decisions about their care.

Read our latest news to find out more about how we are helping to improve the understanding of liver disease.

New publication: Incidence of Complications from Percutaneous Biopsy in Chronic Liver Disease: A Systematic Review and Meta-Analysis Posted: June 16, 2021

NAFLD NASH Liver Disease New publication

New research demonstrates superior performance of LiverMultiScan® for identifying patients with NASH and fibrosis Posted: February 24, 2021

NASH NAFLD LiverMultiScan Liver Disease New publication

LiverMultiScan® could be an alternative to liver biopsy for NASH clinical trials. Posted: February 4, 2021

NAFLD NASH LiverMultiScan New publication ClinicalTrials

Perspectum’s RADIcAL1 trial - addressing the health economic burden of invasive diagnostics for NAFLD and NASH Posted: December 9, 2020

RADIcAL NAFLD NASH LiverMultiScan Liver Disease New publication

New non-invasive MRI biomarker for liver disease could cut costs for drug trials Posted: September 22, 2020

LiverMultiScan Liver Disease NAFLD NASH New publication

First European guidance on the use of multiparametric MRI in fatty liver disease Posted: September 4, 2020

LiverMultiScan Liver Disease NAFLD NASH New publication

Multiparametric MRI: bridging the diagnostic gap for liver disease Posted: August 7, 2020

Multiparametric MRI Liver Disease NAFLD NASH New publication

Quantitative MRI; a game changer for identifying the chronic liver disease patients most at risk of poor clinical outcomes Posted: August 4, 2020

LiverMultiScan Liver Disease NAFLD NASH New publication

The link between type 2 diabetes and liver disease: can screening for NAFLD reduce liver-related mortality? Posted: July 23, 2020

NAFLD Type 2 Diabetes NASH New publication